1. In Vivo
  2. >>Global Vision

Mark Cuban’s US Pharma Ventures: Ally Or Gadfly In The Mix For Indian Firms?

 
• By Anju Ghangurde

Mark Cuban’s newly launched online pharmacy and pharmacy benefit manager operation in the US has sparked interest in India. Can the billionaire entrepreneur’s venture punch above its weight and should Indian firms be watchful?

Alliance
Will Indian Firms Ally With MCCPDC's initiatives ? • Source: Alamy

There is a buzz around billionaire Mark Cuban’s venture, Mark Cuban Cost Plus Drug Company (MCCPDC) and its newly launched online pharmacy, in the US that is extending all the way to India.

That is perhaps not surprising since the activities align with what Indian drug makers have long championed – providing quality medicines at affordable prices. Cuban’s fledgling operations in the US...

But it is still early days and experts in India appear divided and uncertain on what this could potentially mean for domestic pharma firms - should front-line Indian companies potentially...

More from Global Vision

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.